Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Wave Life Sciences
Biotech
GSK continues stockpiling Wave drugs with liver-focused program
GSK is paying Wave Life Sciences $12 million upfront to take ownership of a hepatic program arising from the companies’ long-running collaboration.
James Waldron
Sep 30, 2026 9:19am
Travere chief makes way for former Amicus CEO—Chutes & Ladders
Sep 25, 2026 8:30am
Sanofi, Wave post updates in race to end AATD’s 40-year drought
May 18, 2026 4:30pm
Wave crashes after obesity trial tracks 1% dip in body weight
Mar 26, 2026 9:20am
GSK won't pick up Wave's genetic disease RNA editor
Feb 2, 2026 11:14am
Wave reports AATD win, but investors lukewarm
Sep 3, 2025 3:00pm
